To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
EPICENTRE Biotechnologies Introduces ScriptGuard™ RNase Inhibitor
EPICENTRE Biotechnologies has announced the avalibility of ScriptGuard™ RNase Inhibitor, a defense against common RNases including RNase A, RNase B, and RNase C’s. Its potent affinity for common RNases (Ki>10-14 M) can ensures protection of RNA samples even when trace amounts of RNase are present.
Advanced purification protocols and quality control tests ensure the recombinant ScriptGuard RNase Inhibitor is free of unwanted contaminants that can plague other commercially available preparations of RNase inhibitors.
ScriptGuard RNase Inhibitor does not interfere with enzymes commonly used to prepare or analyze RNA and is more resistant to inactivation by oxidation than other RNase inhibitors.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
